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PURPOSE STATEMENT
Recent progress in the understanding of human autoimmunity provides a solid scientific foundation on which to
base rational therapies for autoimmune diseases. Pemphigus has emerged as a classic example of an autoantibody
mediated disease, and provides an excellent model to study the mechanisms of such diseases and to develop new
options to treat them.
This meeting brought together scientists working on various aspects of human autoimmunity with those working
on pemphigus. Its goal was to review current understanding of the causes and treatments of pemphigus, identify
recent advances in medications and treatments, and identify the most important areas for future research on both
pemphigus and other autoantibody mediated diseases.
A committee was also formed to standardize some of the terminology associated with diagnosis and treatment of
patients.
001
Cell Signaling and Desmosome Assembly/Disassembly Linked to the Generation of
Dsg3-Depleted Desmosomes
Y. Kitajima
Department of Dermatology, Gifu University School of Medicine, Gifu, Japan
We have shown that pemphigus vulgaris (PV)-IgG binding to the cell surface antigens of
keratinocytes (KC) causes PLCgactivation, PIP2 breakdown into diacylglycerol and IP3,
which activate protein kinase C and calcium influx, respectively, and this signaling is linked to
uPA secretion. This study strongly suggests that PV-IgG binding to the cell surface antigens
activates outside-in signaling in KC. Besides this, we examined whether any molecules of
desmosomes are phosphorylated by this or any other signaling. We have found that PV-IgG
phosphorylates Dsg3 and dissociates plakoglobin from Dsg3, leading to Dsg3 breakdown,
which made us speculate the generation of Dsg3-depleted desmosomes. Thus, we have
found out that PV-IgG and monoclonal anti-Dsg3 antibodies (AKmAbs) deplete TritonX-100
soluble fraction of Dsg3 within 20 min and insoluble fraction (desmosomes) within 48 hr
in cultured KC. When PV-IgG and 4 different AkmAbs (AK23, AK20, AK19, AK18) were
compared in terms of Dsg3-depleting activity, PV-IgG-stimulation caused an extreme
reduction (90%) as the ratio of the Dsg3 to PG, and AK23 (the most pathogenic) was a higher
(about 40% depletion) and other AKmAbs showed lower activities proportional to their
pathogenicity. The combination of 4 different AKmAbs augmented the activities more than
any two-AKmAb combination or any single AK mAb stimulation. These results suggest that
the much higher activities of PV-IgG than any of AKmAbs may be due to the polyclonality of
PV-IgG, i.e., varieties and numbers in epitope-sites. Injection of 15 mg per g PV-IgG
decreased the ratio of Dsg3/bcatenin by 30%, which was enough to cause blisters,
histologically and clinically, suggesting that Dsg3-depletion of desmosomes play an
important role blistering in PV. The association of phosphorylation and breakdown of Dsg3
suggest that one of the final out-puts of signaling linked to acantholysis is depletion of
desmosomes of Dsg3. We now know that PV is an signaling disease, but we do not know yet
how PV-IgG binding to the antigens (Dsg3 and possibly others) starts outside-in signaling,
what molecules mediate to activate a variety of signaling mediators (p32MPKK, HSP27, c-
Myc, and PG translocation into nucleus) and apoptosis, and what is the final out-put events of
signaling to cause cell-cell detachment.
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The Interaction of Pemphigus Autoimmunoglobulins with Epidermal Cells – Acantholysis
via Apoptosis First or Cell-Cell Separation and then Apoptosis
Y. Milner1, M. Frusˇic´-Zlotkin1, B. Michel2, M. David3, D. Mimouni3, and F. Bre´ge´ge`re1
1The Myers Skin Biology and Biochemistry Laboratory, Life Sciences Institute, The Hebrew
University of Jerusalem, Israel; 2Michel Skin Care Inc., Beachwood, OH 44122, USA;
3Department of Dermatology, Rabin Medical Centre, Belinson Hospital, Petach Tiqwa, Israel
The mechanism of PV-IgG-induced epidermal skin acantholysis has not been clear as of now.
Several reports from this lab and others [Wang et al. (2004) Apoptosis 9, 131–43; Wang et al.
(2004) FEBS Lett. 567:281–6; Milner et al. (1999) In: The Decade of Autoimmunity, Y.
Schoenfeld, ed., Elsevier Science pp 197–207; Puviani et al. (2003) J Invest Dermatol.
120:164–7] indicated a possible involvement of the FasR/FasL system in epidermal
acantholysis via apoptotic death pathway. We further explore this possibility by using
patients’ skin, skin organ cultures, as well as HaCaT cell cultures. We use immunohistology,
fluorescence microscopy, ELISA and immunoblot techniques to follow the organization of
apoptotic death inducing signaling complexes (DISCs) on keratinocytes surface. Further-
more, kinetics of caspases activation induced by incubation of cell and skin organ cultures
with purified PV-IgG are being followed.
The basic phenomenon of induction of apoptosis in epidermal cells by PV-IgG may be
derived from cell-cell separation in the first stage followed by apoptosis induction. However,
our findings indicate that organization of DISCs precedes cell-cell separation:
Coaggregation of FasR-FasL (FasR,L elevation) was induced by PV-IgG in cultures in cells
still in good cell-cell contact.
Caspase 8 and FADD were also found in the coaggregated state (DISC) in perilesional
patient’s skin without any microscopic evidence for cell-cell separation.
Caspase 8 activation in DISCs in cell cultures incubated with PV-IgG preceded the
activation of caspase 3 (executioner caspase), which coincides with acantholytic lesion
formation.
FasL elicitation and secretion may be the most immediate reason for apoptosis induced by
PV-IgG–this occurs very early when no lesions are apparent.
The involvement of tyrosine kinases(s) was shown by the ability of the inhibitors (possibly of
EGFR) to prevent PV-IgG induced EGFR autophosphorylation, FasL secretion and cell death
in cultures.
The correlation of PV-IgG binding (titers) and Caspase 3 activation in culture was further
proof of the induction of apoptosis by PV-IgG.
Further work is under way to find the signaling pattern facilitating the apoptotic DISC
formation induced by PV-IgG.
003
Apoptotic Mechanisms of Acantholysis in Pemphigus
C. Pincelli
Institute of Dermatology, Department of Medicine, University of Modena and Reggio Emilia,
Modena, Italy
Anoikis is a type of apoptosis characterized by detachment from ECM or cell-cell
detachment. Anoikis plays a critical role in tissue homeostasis and it is thought to be crucial
for cancer development. We have shown that keratinocytes undergo anoikis upon suspension
and this type of apoptosis is accelerated by treatment with anti-13 1 integrin. f31 integrin
exposed to antagonists directly associates with caspase-8 and triggers the activation of the
extrinsic apoptotic pathway, without the involvement of the Fas/FasL system. We have
detected apoptotic keratinocytes in perilesional, yet undetached, pemphigus skin. We have
also shown that pemphigus sera from untreated, but not from steroid treated patients induce
apoptosis in cultured keratinocyte. FasL levels are strikingly increased in sera from untreated
pemphigus patients, as compared to either treated patients or controls. Pemphigus
serainduced keratinocyte apoptosis is partially prevented by pretreatment with either
caspase-8 inhibitor or anti-FasL neutralizing antibody. Moreover, caspase-8 cleavage
induced by untreated pemphigus sera is partially inhibited by anti-FasL antibody. Finally,
untreated pemphigus sera or rFasL induce the cleavage of desmoglein 3 (dsg 3). Taken
together these results suggest that, in pemphigus, keratinocytes undergo apoptosis before
detachment, and that increased levels of FasL in pemphigus sera stimulate the activation of
the caspase-8 extrinsic apoptotic pathway and the cleavage of dsg 3. We speculate that a
type of apoptosis, but not the classic anoikis, is involved in the pathogenesis of pemphigus.
004
Pemphigus 2005: New Ways to Control Acantholysis
D. Rubenstein
Department of Dermatology, University of North Carolina-Chapel Hill School of Medicine
Pemphigus vulgaris (PV) is a life threatening autoimmune blistering disease commonly treated
with potent immunosuppressive medications. Although the autoimmune response in PV
is characterized by the production of antibodies to the desmosome cell-cell adhesion
protein desmoglein-3 (dsg3), the mechanism by which these antibodies cause loss of
adhesion remains undefined. We have identified a signaling pathway initiated by binding
of PV IgG to desmosomes that activates a phosphorylation cascade (p38MAPK !
MAPKAP2 ! HSP27) leading to retraction of the keratin intermediate filaments and actin
cytoskeleton remodeling. Furthermore, we have shown that inhibition of p38MAPK prevents
pemphigus vulgaris IgG induced HSP27 phosphorylation and cytoskeleton remodeling.
These observations suggest that that inhibition of p38 MAPK and HSP 27 phosphorylation
represents a novel, rational, and practical therapeutic approach to treating pemphigus
vulgaris.
005
Cloning and Characterization of Human Monoclonal Antibodies (mAbs) from a
Pemphigus Vulgaris (PV) Patient
J. Stanley, A. Payne, K. Ishii, S. Kacir, C. Lin, H. Li, Y. Hanakawa, K. Tsunoda, M. Amagai,
and D. Siegel
Depts of Dermatology and Pathology, Univ. of Pennsylvania, Philadelphia, and Dermatology,
Keio Univ., Tokyo
PV is caused when autoantibodies against desmoglein (Dsg) 3 and 1 cause loss of
keratinocyte cell adhesion. Further understanding of the pathophysiology of disease and
more targeted approaches to therapy and diagnosis will require more detailed characteriza-
tion of the autoantibodies. To do so, we used phage display to clone human mAbs from a PV
patient. We cloned 43 unique mAbs composed of only 12 clonally-derived heavy chains.
Single chain variable fragment (scFv) antibodies expressing only variable heavy and light (VH
and VL) chains showed immunochemical properties typical of PV antibodies, including
indirect immunofluorescence, Western blotting, and enzyme-linked immunoassay (ELISA)
binding to Dsg3 or Dsg1. Some mAbs bound to both Dsg3 and Dsg1, demonstrating that
these Dsgs share common epitopes that can be targeted by the same PV antibody. We tested
pathogenicity of the mAbs in a neonatal mouse model of disease and in a human keratinocyte
dissociation assay. Most antibodies were not-pathogenic, but we isolated various mAbs that
disrupted adhesion of either Dsg3 alone, Dsg1 alone or both Dsg3 and Dsg1. The mAbs
showed marked genetic restriction in heavy and light chain gene segment usage, with
different gene usage between antibodies that bound Dsg3, Dsg1, or both and those that were
pathogenic and non-pathogenic. Many antibodies showed somatic mutations through affinity
maturation. However, different antigen and functional specificities were not derived from
somatic mutations, but rather from different parental B cell clones. Pathogenic mAbs tended
to bind the amino-terminus of Dsgs. Sera from other pemphigus patients bound the same or
similar epitopes as these mAbs. These studies show that pathogenic antibodies from PV
patients are genetically restricted and suggest ways of targeting therapy and diagnosis to
their limited repertoire.
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Lessons from Animal Models of Pemphigus
M. Amagai
Department of Dermatology, Keio University School of Medicine
Pemphigus vulgaris (PV) is an autoimmune bullous disease caused by IgG autoantibodies
against desmoglein 3 (Dsg3). It remains to be elucidated how tolerance regulates
autoreactive B cells against peripheral antigen such as Dsg3. In this study we attempted
to clarify the mechanism of B cell tolerance against Dsg3 using Dsg3-specific AK7 B cell
transgenic (AK7-Tr) mice. AK7 is an IgG monoclonal antibody (mAb) isolated from PV mouse
model but is non pathogenic and unable to induce PV blisters when hybridoma cells were
inoculated in peritoneum. AK7 was expressed on IgM backbone in AK7-Tr mice. In AK7-Tr
mice, Dsg3-specific AK7 B cells were detected in the peripheral lymphoid organs, such as
spleen and lymph nodes, without elimination or inactivation. However, surprisingly, when
AK23 mAb that is pathogenic and able to induce blisters was injected into AK7-Tr mice, AK7
B cells disappeared from spleen and lymph nodes within a week following development of PV
phenotype. In contrast, when AK7 or AK9 mAb, which is not pathogenic, was injected, there
was no disappearance of AK7 B cells. To investigate cellular mechanism in the elimination of
AK7 B cells by pathogenic AK23 mAb, AK7-Tr mice were crossed with Rag2/ mice, which
have no mature T or B cells. In Rag2/ AK7-Tr mice, the elimination of AK7 B cells by AK23
mAb was significantly diminished. Transfer of CD4þTcells from wild type to Rag2/ AK7-Tr
mice restored the elimination, suggesting a possible role of CD4þT cells in this process.
These findings indicate that self-reactive B cells exist in the periphery unless they are not
harmful to the body. But once the body senses danger signals there is a mechanism that
eliminated the self-reactive B cells in an antigen-specific way. Further clarification of this
novel B cell tolerance mechanism will allow us to develop novel therapeutic strategies against
autoimmune diseases.
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Autoaggressive and Regulatory T-Cells in the Pathogenesis of Pemphigus Vulgaris
M. Hertl, R. Eming, and C. Veldman
Department of Dermatology, Philipp’s University, Marburg, Germany
The focus of our group is to characterize the involvement of T helper (Th) cells in the immune
pathogenesis of pemphigus vulgaris (PV). Current concept support the idea that
autoaggressive Th2 cells specific for desmoglein 3 (Dsg3)/Dsg1 are required to foster auto-
ab production by autoasggressive B cells. PV is presumably the consequence of a loss of
tolerance against Dsg3/Dsg1 on the B cell rather than the T cell level since Dsg-specific Th
cells are present both in PV patients and healthy carriers of PV-associated HLA class II
alleles.
Noteworthy, Th cells from patients and healthy donors recognize identical epitopes of the
Dsg3 ectodomain and their activation is restricted by the PV-associated HLA class II alleles,
HLA-DR10402 and DQ10503. Ongoing studies aim at detecting autoaggressive Th cells
utilizing HLA class II-Dsg3 peptide tetramers. This approach will be extremely helpful to
follow up on autoaggressive T cells as an immediate therapeutic marker in PV patients on
immunosppressive treatment.
Recently, our group identified Dsg3-specific type 1 (Tr1) regulatory T cells that are
presumably critical for the maintainance of tolerance against Dsg3 because there is a much
lower Dsg3-specific Tr1/Th2 ratio in the PV patients than in healthy individuals. These Tr1
cells constitutively express the transcription factor Foxp3 which is virtually absent in the
Dsg3-specific autoaggressive Th2 cells. Antisense-induced inhibition of Foxp3 expression
converted the Dsg3-specific Tr1 cells into autoaggressive Th2 cells: Antisense treatment led
to a loss of phenotypic markers of Tr cells and induced the secretion of IL-2 and the Th2
cytokines IL-5 and IL-10. Moreover, Foxp3 antisense treatment rendered the formerly anergic
Tr1 cells responsive to Dsg3 and abrogated their suppressor activity on autoaggressive
Dsg3-specific Th2 cells.
Thus, T cell-targeted approaches such as anergy induction of autoaggressive Th cells
utilizing Dsg peptide-based strategies and the conversion of autoaggressive Th2 cells into Tr1
cells by induction of Foxp3 expression may provide refined and highly effective tools to
induce specific tolerance against Dsg3 in PV.
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Elevation of Antigen Speciﬁc CD8þCD28- Cells in Newly Remittent Patients with
Pemphgus Vulgaris
Sinha, E. Lee, C. Rizzo, R. Dionisio, D. Nguyen, S. Chow, and A. Spizuoco
Dermatology, Weill Medical College of Cornell University, New York, NY, USA.
Pemphigus vulgaris (PV) is a blistering skin disease mediated by autoantibodies targeting
desmoglein 3 (Dsg3). Production of anti-Dsg3 antibodies in active disease relies, in part, on
the activation of Dsg-3-specifc Th-2 CD4þcells. The cellular immune mechanisms
responsible for the remittent disease state are unknown. We have observed an immune
deviation towards a Th-1 type response as well as an antigen specific elevation in IFN-g
secretion by a CD4- population, which later correlated to a CD8þpopulation, in association
with remittent disease. We evaluated peripheral blood mononucleocytes (PBMC) from five
patients with active disease, three newly remittent patients, five long-term remittent patients,
six healthy HLA-matched controls, and seven healthy HLA-unmatched controls for IFN-g
secretion in response to stimulation with Dsg3, superantigenic stimulation with SEB, and no
stimulation. Using cell surface matrix technology to isolate rare activated cytokine-secreting
cells in combination with flow cytometric analysis, we detected a significant elevation in IFN-g
secretion by CD8þCD28- cells in newly remittent patients in response to Dsg3. PBMCs from
two patients exhibit an elevation in FoxP3þCD8þ cells but no elevation in intracellular
perforin was detected in CD8þ cells with Dsg3 stimulation, suggesting that the increase in
CD8þCD28- activity in newly remittent patients is associated with a suppressor response
rather than cytotoxicity. The antigen-specific increase in IFN-g secretion by CD8þCD28-
observed in newly remittent patients was not detected in active, long-term remittent patients
or healthy controls.
009
Desmocollins as a Target Antigen in Acquired Autoimmune Bullous Diseases
T. Hashimoto, B. Oyama, and M. Amagai
Departments of Dermatology, Kurume University School of Medicine and Keio University
School of Medicine
Desmosomal cadherins are divided into desmogleins (Dsg) and desmocollins (Dsc). It is now
well known that the antigen for pemphigus foliaceus is Dsg1 and antigen for pemphigus
vulgaris is Dsg3. Dsc consists of three different isoforms, Dsc1-Dsc3, each of which has two
molecules, a longer a-form and a shorter b-form. On the other hand, IgA pemphigus is
divided into two major types, subcorneal pustular dermatosis (SPD) type and intraepidermal
neutrophilic IgA dermatosis (IEN) type.
We have shown that the target autoantigen for SPD type of IgA pemphigus is Dsc1 by
cDNA transfection method using COS-7 cells and Dsc cDNAs. In the next step, we have
developed enzyme-linked immunosorbent assay (ELISA) using recombinant Dsc proteins
produced by vaculovirus expression system. By this ELISA, we have shown that Dsc1-3 are
reacted by IgG and IgA antibodies of atypical pemphigus sera, but not by IgG antibodies of
classical types of pemphigus.
Curiously, most of the SPD type IgA pemphigus sera did not show positive reactivity with
Dsc1 by the ELISA, although all of them reacted with Dsc1 by cDNA transfection. Therefore,
we have developed immunoprecipitation for IgA antibodies using secreted form of Dsc1 by
transfection to mammalian cells. Even in this immunoprecipitation system, IgA antibodies of
SPD type IgA pemphigus did not immunoprecipitate Dsc1. At the present, the reason for this
inconsistent result is not known.
010
In search of the Etiology of Autoimmune Pemphigus
L. Diaz
Department of Dermatology, University of North Carolina School of Medicine, Chapel Hill,
NC
Our research group has been studying FS in Brazil for several years and has identified an
Amerindian reservation of Limao Verde with a population of 1,200 inhabitants, where the
prevalence of FS is 3.4%. This reservation is the home of the Terena tribe; native settlers of
the State of Mato Grosso do Sul. Using the sensitive ELISA assay, we detected anti-Dsg1
antibodies in serum of patients before the onset of clinical disease as well as in 55% of
unaffected individuals living in this reservation. These anti-Dsg1 antibodies detected in the
pre-clinical stage of FS belong to the IgG1 and IgG4 subclasses and recognize the COOH-
terminal EC5 domain of the molecule. Remarkably, disease onset is associated with a
significant increase of IgG4 antibodies that recognize the NH2-terminal EC1-2 domains of
Dsg1.
A recent case-control epidemiological study conducted in the Limao Verde reservation
suggests that hematophagous insects (kissing bugs, sand and black flies) are potential risk
factors for this disease. Interestingly, we have recently reported that anti-Dsg1 autoanti-
bodies are detected in patients with tropical parasitic diseases mediated by three
hematophagous vectors: onchocerciasis (black flies), leishmaniasis (sand flies) and Chagas
disease (kissing bugs) (6). The anti-Dsg1 autoantibodies present in the serum of these
patients also recognize the EC5 domain of Dsg1, like those detected in unaffected individuals
living in the Limao Verde reservation. The three blood-feeding insects (simuliids,
phlebotomines or triatomines) are all found in the Limao Verde reservation. It was also
demonstrated that the FS sera do not react with the disease causing parasites (filaria,
leishmania of trypanosome). Based on these findings we hypothesized that a hematophagous
insect product (saliva?), cross-reactive with the EC5 domain of human Dsg1, triggers an early
non-pathogenic autoantibody response in humans. In certain genetically predisposed
individuals, this response would spread to involve the EC1-2 domain of Dsg1 and trigger
pathogenic autoantibody response and FS. However, the common presence of the
hematophagous insects in other regions of the world and rarity of FS requires further
investigation.
Among the different phenotypes of pemphigus, FS offers the unique opportunity to uncover
the underlying mechanisms controlling the genetic and environmental interactions leading to
autoimmune diseases in humans.
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Molecular Mechanisms of Drug-Induced Pemphigus
M Mignogna1, S. Fedele1, and V Ruocco2
1Oral Medicine Section, Department of Odontostomatological and Maxillofacial Sciences,
University ‘‘Federico II’’ of Naples, Naples, Italy; 2Department of Dermatology, Second
University of Naples, Naples, Italy.
The ability of some drugs to cause or exacerbate certain autoimmune diseases is a well
known, even if poorly understood, event. Over the last decade important findings have been
obtained in understanding the biochemical mechanism underlying drug-induced pemphigus
and, more recently, molecular studies have identified NOS-triggered apoptosis as a major
cellular event implicated in both biochemical and immunological acantholysis. In addition,
increased expression of heat shock protein 70, upregulation of c-myc and p53 expression,
and inhibition of the keratinocyte transglutaminase gene have been described in apoptotic
death triggered by treating keratinocytes with either 15 mmol L-1 captopril or with PV serum,
and offer new interpretation of acantholytic process, elucidating further aspects of the
molecular mechanism involved in pemphigus pathogenesis. With regard to clinical and
applicative aspects, the implications of these findings are yet to be clarified and major
difficulties arise in daily practice toward managing the potential influence of some drugs in
both pemphigus onset and exacerbation. It has not understood why withdrawal of drug
suspected to cause the disease does not lead to spontaneous recovery in some patients,
whereas in others clinical remission does occur even associated with decline in autoantibody
production. As a consequence, currently only 25% of clinicians expert in pemphigus
treatment is reported to attempt to eliminate potential triggers before commencing
corticosteroid therapy. Furthermore, serious clinical difficulties often emerge when drugs
known to be associated with pemphigus induction and exacerbation, such as some
antibiotics or antiinflammatory drugs, are needed to be necessary to cope with side effects or
conditions associated with pemphigus and its management.
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Exogenous Factors Inﬂuencing Pemphigus
S. Brenner
Dept of Dermatology, Sourasky Medical Center, Tel Aviv, Israel
We created an Acronym for Pemphigus as follows:
Pe – Pesticides
M – Malignancy
P – Pharmacology (Drugs)
H – Hormones
I – Immunization & Infection
G – Gastronomy
U – UV radiation
S – Stress
All these factors should be eliminated in order to alleviate the disease.
Each of these factors will be discussed.
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Lessons Learned from Idiopathic Thrombocytopenic Purpura (ITP)
D. Siegel
Department of Pathology & Laboratory Medicine, University of Pennsylvania School of
Medicine, Philadelphia, PA
Like pemphigus, ITP is an autoimmune disease that results from the production of pathogenic
autoantibodies. In the case of ITP, the autoantibodies are platelet-specific and induce the
clearance of antibody-coated platelets by the spleen. Like pemphigus, therapy comprises
immunosuppression which is non-specific and can be toxic. Though much had been learned
about ITP through the study of patient sera, the key to developing more specific therapy
required an understanding of human pathogenic monoclonal antibodies (mAbs) on a
molecular genetic level. Such data, comprising immunoglobulin gene usage, clonality, fine
specificity, etc. within a given patient and across patients, could not be obtained by the
analysis of polyclonal patient sera that contained an admixture of pathogenic and non-
pathogenic antibodies. To clone ITP patient mAbs, we utilized phage display, a molecular
method for cloning immune repertoires that avoided the inherent difficulties in producing
human mAbs by hybridoma technique (Blood 2002;100:1388). Using this approach, we were
able to clone large arrays of human platelet mAbs, the genetic analysis of which revealed
evidence of clonal expansion, somatic mutation, and common structural features within and
across patients that we are currently using as leads for the creation of novel therapies. With
these laboratory tools in hand and immunological principles in mind, we have now begun to
apply the lessons learned from ITP to the study of pemphigus. Our initial set of results have
been recently published (J. Clin. Invest. 2005;115–888) and have already provided critical
insights into the characteristics of anti-desmoglein pathogenic autoantibodies that may be
exploited for the purpose of designing targeted therapy (see accompanying abstract by
Payne et al.) techniques and lessons, principles.
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Epidemiology of Pemphigus and Pemphigoid
M. Pittelkow and M. al Hashimi
Department of Dermatology, Mayo Clinic, Rochester MN, USA.
The epidemiology of pemphigus and pemphigoid has been variably investigated worldwide.
Incidence rates for pemphigus range from 0.08 (Finland) to 1.6 (Jerusalem) per 100,000/yr.
The only US study (CT) calculated a crude incidence of 0.42 per 100,000/yr. Incidence rates
for pemphigoid are very limited, ranging from 0.6–0.9 per 100,000/yr for Germany and
France, respectively. No detailed US study of pemphigoid incidence has been reported. The
Rochester Epidemiology Project (REP), utilizing the well defined population demographics
and healthcare record systems of Olmsted Co. MN, provides a unique resource to
simultaneously determine the overall and age-adjusted incidence rates and further compare
the epidemiology of these two distinct autoimmune blistering diseases. Over 5 decades
(1950–2000) incident cases of pemphigus and pemphigoid were identified and confirmed by
histology and immunopathology. The overall age- and sex-adjusted incidence rates for
pemphigus and pemphigoid were 0.35 and 2.4 per 100,000/yr, respectively. Whereas the
rates were similar for increasing age (by decade) for pemphigus, the rates increased
dramatically for pemphigoid, from o1 (40–49 yrs) to 76 (90–99 yrs) per 100,000/yr. More
woman than men (1.4:1) developed pemphigus or pemphigoid. For the Olmsted Co.
population, the overall incidence of pemphigoid was 7-fold that of pemphigus. There was no
marked increase in incidence with age for pemphigus, but pemphigoid dramatically increased
over 100-fold for the oldest vs. youngest age groups. Potential risk factors of development as
well as mortality, associated disease, treatment and outcomes are under investigation.
015
Searching for Evidence in the Treatment of Pemphigus
M. Jonkman, G. To´th, and L. Mentink
Department of Dermatology, University Medical Center Groningen, University of Groningen,
Groningen, the Netherlands
Objective: In searching for evidence in the treatment of pemphigus, to date five randomized,
non-blinded, trials have been performed to assess the value of various adjuvant therapies on
top of prednisone. The results in all of these studies showed no significant better outcome of
the study medication. We undertook the first randomized, double-blinded, placebo-
controlled trial in pemphigus.
Methods: Within 2000–2005 patients with pemphigus vulgaris (PV) were randomized in
multiple centers for either 300 mg oral dexamethasone (DP) or placebo pulses (PP) 3 days per
month. All patients received in addition prednisolone 80 mg per day according to tapering
schedule and azathioprine 3 mg per kg per day. Monthly pulses were continued until
prednisolone was tapered to zero, in minimal per protocol 19 weeks (complete remission).
The follow-up period was 1 year.
Results: After randomization, 11 patients were included in the DP arm, whereas 9 patients in
the PP arm. Eight patients treated with DP and nine with PP reached complete remission
during the study. Mean time to complete remission was 173 days with DP and 175 days with
PP. The mean duration of complete remission within the first year was 150 days for DP and
141 days for PP. Mean cumulative prednisolone usage was 5300 mg in DP and 4882 mg in PP
after one year. 30 adverse events, were recorded in 10 patients on DP, versus 14 adverse
events in 5 patients in the PP group. Weight gain (45%) occurred 8 times to patients treated
with DP, versus one patient on PP. No statistical significant differences (po0.05) between the
groups, nor a tendency of an adjuvant effect of DP on remission of pemphigus vulgaris was
found.
Discussion: We conclude that we were unable to show the benefit of oral dexamethasone
pulse therapy as adjuvant treatment in pemphigus vulgaris.
016
New Approaches to Prevent Pemphigus Acantholysis
S. Grando
Department of Dermatology, University of California Davis, USA.
Acantholysis in pemphigus develops secondary to an autoantibody binding to keratinocyte
plasma membrane both in the desmosomal and interdesmosomal areas. By immunopreci-
pitation and western blotting, pemphigus IgGs bind to an array of keratinocyte proteins. The
known targets include both the structural and signaling proteins, such as desmogleins and
acetylcholine receptors, respectively. Acantholysis starts from retraction of tonofilaments,
followed by widening of the intercellular spaces at the interdesmosomal areas with
desmosomes remaining intact. Cell shrinkage is followed by ripping off yet intact
desmosomes, disappearance of desmosomes and cell rounding up. Since anti-desmoglein
3 antibody causes a desmosomal split without keratin retraction, acantholysis in patients
cannot be an effect of this antibody alone. Rather, it is a result of a complex biochemical
event evoked due to binding of autoantibodies to several types of self-antigens on the
keratinocyte plasma membrane. The therapeutic efficacy of corticosteroids in pemphigus
harbors direct anti-acantholytic effects. A non-steroidal treatment of pemphigus can be
achieved by pharmacologically interceding at the intracellular biochemical events mediating
the acantholytic action of pemphigus autoantibodies. Pemphigus acantholysis can be
prevented without administration of corticosteroids by 1) eliminating disease-causing
autoantibodies, 2) blocking the anti-oncotic and anti-apoptotic pathways, 3) inhibiting
phosphorylation of cell proteins and 4) upregulating the keratinocyte adhesion through the
cholinergic pathways.
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Pemphigus: Newer Immunosuppresants
CH Nousari
Voluntary Associate Professor-Department of Dermatology. University of Miami Director-
Institute for Immunofluorescence. DermPath South Florida Diagnostics
The safest and the most effective therapy in the treatment of autoimmune diseases could be
achieved through ultraselective immunomodulatory and not immusuppressive therapy (arrow
therapeutic window and thus organ toxicity, risk infections and neoplasms). Currently, this
goal is partly achieved by the use of additive/synergistic combinations of standard
immunosuppresants that lack overlapping toxicities. Biologics encompassed a new group
of bioenginereed agents with a more selective immunologic mechanism of action, long half
life, low immunogenicity, and a safe short; and apparent long; term profile. The biologics that
have a current potential role in the management of antibody mediated autoimmune diseases
like pemphigus are rituximab (Rituxan) and alemtuzumab (Campath(R), Mabcampath (R))
which are non-conjugated IgG1 monoclonal antibodies directed against the CD20 (B cells)
and CD52 surface antigens (B and T cells) They are commonly used in the therapy of indolent
B-cell non-Hodgkin’s lymphoma (B-NHL) and of B-cell chronic lymphocytic leukaemia,
Rituximab has shown preliminary but promising results in pemphigus (vulgaris/foliaceus/
paraneoplastic) and other antibody mediated autoimmune diseases (hemolytic-uremic
syndrome diopathic thrombocytopenic purpura, systemic lupus erythematosus, autoimune
hemolytic anemia, and dermatomyositis). Alemtuzumab, on the other hand, has proven to be
effective in graft versus host disease and in paraneoplastic pemphigus. Biologics targetting
costimulatory molecules (belatacept, alefacept, efalizumab) and T cells receptors (daclix-
umab/basiliximab) may also have a potential therapeutic role if used in combination, in
pemphigus.
Biologics offer a rational translational therapeutic mode in the search for reconstituting
immune tolerance in autoimmune diseases.
018
Pemphigus – Mycophenolate Mofetil
D. Mimouni
Autoimmune bullous diseases clinic, Department of Dermatology, Rabin Medical Center,
Israel
The introduction of corticosteroids for the treatment of pemphigus has changed this
previously lethal disease into a treatable one. However, significant morbidities and even
mortality still occur, primarily due to the adverse effects of long term corticosteroid therapy.
Mycophenolate mofetil (MMF) is increasingly being employed as a corticosteroid-sparing
agent in pemphigus vulgaris and foliaceus.
Because of its effectiveness and safety profile, MMF has now replaced azathioprine as the
antimetabolite adjuvant of choice in the treatment of many autoimmune and inflammatory
disorders including pemphigus.
Recently, there have been several studies, case reports and a small series with short-term
follow up of pemphigus patients successfully treated with MMF.
We report our successful experience in the treatment of 42 PV and pemphigus foliaceus
(PF) patients with MMF as the adjuvant steroid sparing agent. The dosage that was used in
our patients was the FDA approved dose of MMF for cardiac-transplant patients (3000 mg
per d). We also report on the international, multicenter ongoing prospective, randomized,
double-blind, placebo-controlled study that was launched to assess efficacy and safety of
MMF compared to placebo in PV patients receiving prednisone.
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Randomized Placebo-Controlled Clinical Trial of Capsone as a Glucocorticoid-Sparing
Agent in Maintenance Phase Pemphigus Vulgaris
V. Werth, D. Fivenson, A. Pandya, D. Chen, J. Rico, J. Albrecht, and D. Jacobus
Multicenter.
A number of case series have proposed dapsone as a steroid-sparing agent in pemphigus
vulgaris. In the current study, the efficacy of dapsone was assessed in a randomized placebo-
controlled trial. We now report a trial with 19 patients enrolled among 5 centers. Inclusion
criteria were biopsy and direct immunofluorescence-proven pemphigus vulgaris controlled
with glucocorticoids and/or cytotoxics, disease in maintenance phase, and age 18 to 80
years. Physicians had tried at least two tapers of glucocorticoids unsuccessfully and had 30
days of stable (o10% variation) steroid dosage of 15 mg QD or 20 mg QOD at enrollment.
No pulse steroid treatment, pulse cytoxan, or plasmapheresis within 2 mos of enrollment was
allowed. Patients unable to taper glucocorticoids by more than 25% within 4 months were
declared a failure, and allowed to switch to the opposite medication while maintaining the
double blind. The primary outcome measure was the ability of patients to taper to  7.5 mg
per day within one year of reaching the maximum dosage of the study drug. Blinded clinical
monitors observed the laboratory values. Of the 9 patients on dapsone, 5 succeeded, 3
failed, and 1 was a drop-out. Of the patients on placebo, 3 succeeded and 7 failed. This
primary endpoint favored the dapsone-treated group, but was not statistically significant
(p¼ 0.18). 3 patients who failed on placebo crossed over to dapsone. Of these, all succeeded
after crossover to dapsone treatment. We found that overall 8/11 (73%) of patients receiving
dapsone vs 3/10 (30%) receiving placebo reached the primary outcome of a prednisone dose
7.5 mg per day. Overall side effects included a drug rash (1 patient), paresthesias potentially
related to dapsone (1), and dyspnea secondary to methemoglobinaemia (1). In conclusion,
this trial demonstrates a trend to efficacy of dapsone as a steroid-sparing drug in
maintenance phase pemphigus vulgaris, and defines parameters for planning future PV trials.
Age at enrollment
Length of time with disease
Women vs men
Dose of prednisone in each group at onset and at end.
Maximum of dose (history)
Minimum dose prior to study entry
Severity of original disease (oral vs skin)
Antibody titer.
020
Mechanisms of IVIG Action in Human Autoimmune Blistering Diseases
Z. Liu, N. Li, M. Zhao, J. Hilario-Vargas, P. Prisayanh, S. Warren, D. Roopenian, and L. Diaz
Department of Dermatology, University of North Carolina-Chapel Hill, Chapel Hill, NC, and
The Jackson Laboratory, Bar Harbor, ME, U.S.A.
Numerous mechanisms of action have been proposed for intravenous immunoglobulin (IVIG)
in the treatment of autoimmune and inflammatory diseases. Bullous pemphigoid (BP),
pemphigus foliaceus (PF), and pemphigus vulgaris (PV) are organ-specific antibody-mediated
autoimmune diseases in which autoantibodies target BP180, desmoglein-1, and desmoglein-
3, respectively. In this study, we used the passive transfer murine models of BP, PF, and PV to
test whether IVIG in these autoantibody-mediated skin diseases accelerates the degradation
of pathogenic IgG through the neonatal Fc receptor (FcRn) pathway. The FcRn mediates IgG
transmission from mother to the fetus and passage across the neonatal intestine and protects
circulating IgG from catabolism. We found that FcRn-deficient mice were resistant to
experimental BP, PF, and PV. Circulating levels of pathogenic anti-BP180, anti-Dsg1 and anti-
Dsg3 in FcRn-deficient mice were significantly reduced compared to WT mice. Administration
of IVIG to WT mice prevented blister formation triggered by pathogenic IgG in WT mice. This
protection was associated with a significant reduction of circulating pathogenic IgG. The
protective effect of IVIG depends on FcRn activity because pathogenic IgG levels at 24 and
48 h post-injection were similar in FcRn-deficient mice with and without IVIG treatment.
These data demonstrate that IVIG treatment leads to increased FcRn-dependent clearance of
pathogenic IgG. This mechanism may account for beneficial effects of IVIG in many
autoantibody-mediated diseases.
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Enhancing the Effectiveness of IVIg with Cytotoxic Agents
JC Bystryn
Dept of Dermatology, NYU School of Medicine
Intravenous immunoglobulin (IVIg) treatment of pemphigus vulgaris (PV) causes a rapid
decrease in circulating pemphigus antibodies. This suggests that a rebound in the level of
these antibodies, following the treatment, may limit the effectiveness of IVIg and that
suppression of the rebound with a cytotoxic drug could improve the effectiveness of the
procedure.
To evaluate this possibility, we examined the effects of IVIg on serum levels of intercellular
(IC) antibodies and on clinical response in patients with active PV treated identically with IVIg
given with or without an effective dose of cytotoxic drug. Twelve pts with active PV
unresponsive to conventional therapy with systemic steroids were treated with a single cycle
of IVIg (400 mg per kg per day for 5 days). Nine patients were concurrently given
cyclophosphamide (n¼ 8) or azathioprine (n¼ 1) at 50 mg per TID. Three patients were
treated similarly with IVIg but given no (n¼1) or inadequate doses (n¼2) of these agents.
Serum levels of IC antibodies decreased by an average of 73% from baseline level within 1
week of initiating IVIg in the 9 pts given a cytotoxic drug compared to 0% decline in the 3 pts
given none or an inadequate dose. In the patients treated without a cytotoxic drug, IC
antibodies decreased by 50% within 1 week when IVIg was repeated together with
cyclophosphamide. Two wks following initiation of IVIg, skin lesions were healed by 30% or
more in over 80% of pts treated with a cytotoxic drug vs in none of pts that received an
inadequate dose.
These results suggest that cytotoxic drugs improve the ability of IVIg to rapidly lower
pemphigus antibodies and to control active PV unresponsive to conventional therapy.
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Use of Intravenous Immunoglobulin Therapy in the Long-term management of
Pemphigus Vulgaris
AR Ahmed
Harvard School of Dental Medicine, Dir. Center for Blistering Diseases, New England Baptist
Hospital, Boston, MA
Intravenous immunoglobulin (IVIg) therapy has recently become an option in the long-term
management of certain patients (pts.) with pemphigus vulgaris (PV). The indications for the
use of IVIg are 1) pts. who have failed conventional immunosuppressive therapy (CIST), 2)
pts. who have developed significant side effects from CIST, and 3) pts. in whom CIST is
contra-indicated. IVIg is used according to a published protocol (Arch Dermatol.2003;139:
1051–1059). The dose is 2 gm per kg per cycle. The cycles are repeated at 3–4 week intervals
until new lesion formation ceases and lesions are healing. Then the intervals between cycles
is increased to 6,8,10,12,14 weeks. The end-point of therapy is the 16-week interval cycle. In
44 patients treated, the mean number of cycles to control has been 6.7 and the total cycles
required for treatment are 21.5. Pts. have remained in remission for a mean of 4.3 years. While
IVIg is associated with some serious side effects, no such side effects were observed in these
patients. The reasons for successful out-comes are; a) extensive, rigorous, frequent, and
careful topical care at each site of disease b) use of sublesional corticosteriod injections c)
diet management d) frequent cultures of non-responsive lesions and use of systemic
antibiotics e) use of same liquid IVIg commercial preparation f) repeated patient education
and g) careful screening of patients before initiating therapy, and monitoring patient during
the infusion. Failures in the literature are often difficult to identify because in many patients it
is not IVIg only but all other drugs used that have failed. Pts. treated with IVIg may be high,
medium, low responders and non-responders. The ideal site for the administration of IVIg is
the office of a physician who is familiar with pemphigus and IVIg.
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An Open-Label Phase I Clinical Study to Assess the Safety of PI-0824 in Patients with
Pemphigus Vulgaris
G. Anhalt, V. Werth, B. Strober, M. Connolly, N. Korman, D. Greenstein, J. Fantasia, and R.
Kalish
Multicenter
An open-label phase I study was conducted at 8 centers to assess the safety of desmoglein-3
synthetic peptide (186-204) (PI-0824), in patients with PV requiring daily corticosteroid
therapy. Biological responses, including anti-desmoglein 3 (Dsg3), and the number of Dsg3
specific CD4þT cells, were evaluated for possible early indication of biological activity. IgG
subsets IgG1(no – total IgG only) and IgG4 specific for Dsg3 were also evaluated.
Peptimmune, Inc., Cambridge, MA, has developed PI-0824, the immunodominant T-cell
epitope of Dsg3, as a specific peptide immunotherapy for the treatment of PV. PI-0824 is a
synthetic peptide homologous to a portion of the human Dsg3 molecule. The goal of infusion
with tolerizing doses of PI-0824 is to selectively suppress the production of anti-Dsg3
antibodies through inactivation of and/or deletion of disease-associated CD4þT-cells. A total
of 17 patients, in 3 groups of up to 6 patients, each received two IV infusions of 0.4, 2.0, or
10.0 mg per kg PI-0824 separated by 7 days. No serious adverse events (SAEs) or infusion-
associated reactions (IARs) were reported. A total of 4 disease flares were experienced, 2
prior to treatment with study drug, and 2 one to 5 months post-treatment. No significant
changes in anti-Dsg3 antibody titers were noted from pre-treatment levels. No appreciable
changes in anti-Dsg antibodies were noted, but the duration of therapy may not have been
long enough to see sustained effects on antibody production. Future studies will evaluate the
role of longer-term treatment, as well as further dose ranging investigations.
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P001
ELISA Test in Pemphigus: Diagnostic Value and Relationship with Clinical Findings
M. Barnadas, M. Gonza´lez, L. Puig, M. Agustı´, C. Gelpı´, and A. Alomar
Departments of Dermatology and Immunology. Hospital Sta. Creu i St. Pau (Barcelona)
Spain.
Introduction. Diagnosis of pemphigus vulgaris (PV) and foliaceus (PF) is established by
means of direct immunofluorescence. The Elisa test for the detection of anti-desmoglein 1
and anti-desmoglein 3 antibodies markedly improves diagnosis of PV and PF. We report our
experience in the use of this tecnique.
Patients and methods. We revised 25 PV patients and 3 PF patients whose sera were studied
with the Elisa test. The commercial kit MBL, which recognizes desmoglein 1 and desmoglein
3 epitopes, was used for the study. Ten normal sera and 20 sera from patients with various
pathologies were studied as controls.
Results. All PV patients had anti-desmoglein 3 antibodies and 9 of them also had anti-
desmoglein 1 antibodies. Six patients with cutaneous lesions also showed anti-desmoglein 1
antibodies. The three PF patients had anti-desmoglein 1 antibodies only. One PV patient
initially had oral ulcerations only, but developed extensive cutaneous lesions in parallel with
the increase in anti-desmoglein 1 antibodies level. In the course of the disease, two PV cases
presented cutaneous lesions but without mouth ulcers and this moment, only anti-demoglein
1 antibodies were detected. No circulating antibodies were detected in the normal 10 sera
nor in the 20 patients with other pathologies.
Conclusions. Detection of anti-desmoglein 1 and 3 antibodies has a high diagnostic value
and patients can be classified as PV or PF from the positivity pattern.
P002
Therapy of Paraneoplastic Pemphigus with Rituximab: A Case Report and Review of
Literature
M. Barnadas, E. Roe, S. Brunet, P. Garcia, P. Bergua, L. Pimentel, L. Puig, A. Francia,
R. Garcı´a, C. Gelpı´, J. Sierra, P. Coll, and A. Alomar
Departments of Dermatology, Clinical Haematology, Internal Medicine, Immunology,
and Microbiology. Hospital Sta. Creu i St. Pau (Barcelona) Spain
Paraneoplastic pemphigus (PNP) is an autoimmune blistering disease with poor prognosis
when associated with malignant neoplasm.
We report the case of a patient with PNP associated with a CD20þ non-Hodgkin follicular
lymphoma that was treated with Rituximab plus corticosteroids and short courses of
cyclosporine. One and a half years after therapy with Rituximab, clearance of the oral
ulcerations was complete and oral methilprednisolone was slowly tapered down without
further recurrences. In the course of the disease, the patient developed sepsis due to Listeria
monocytogenes and viral infections by human herpes virus 1 and human herpes virus 3. At
the end-stage of the disease she suffered a cutaneous infection by Mycobacterium chelonae.
The patient died two years and seven months after the onset of PNP. Rituximab may be useful
for therapy of PNP, but further studies are necessary to confirm this hypothesis.
A review of literature of PNP patients treated with Rituximab is presented.
P003
A Retrospective Study: The Impact of a Local Pemphigus Support Group on Health Care
Delivery
B. Bince, A. Co, C. Fernandez, G. Bardelosa, and J. Rebullida
Jose R. Reyes Memorial Medical Center, Department of Dermatology, Manila City,
Philippines
The Pemphigus Support Group of the Jose R. Reyes Memorial Medical Center (JRRMMC)–
Department of Dermatology was organized in 2002 spearheaded by Dr. Benjamin B. Bince.
This support group was established with the objective of educating patients diagnosed to
have autoimmune blistering diseases and fostering awareness among resident physicians
regarding this illness.
This retrospective study aims to determine if the objectives of this support group were met.
All charts of patients with autoimmune blistering diseases at the JRRMMC from 1999–2004
were collected. Data gathered showed an increasing trend in the number of newly diagnosed
cases and the number of follow-ups.
In conclusion, we believe that the increase in the number of detected cases and follow-ups
may be utilized to demonstrate an improvement in the delivery of health care among patients
with autoimmune blistering diseases.
P004
Measuring Quality of Life in Pemphigus Using the SF-36 Questionnaire
G. Cianchini, A. Mozzetta, V. Antinone, S. Tabolli, F. Sampogna, P. Puddu, and D. Abeni
Laboratory of Health Services Research.Dept. of Immunodermatology Istituto Dermopatico
Dell’immacolata, Rome-Italy
Although it is known that pemphigus severely affects patients, very few data are available
actually estimating the impact of this disease on quality of life (QoL). The aim of our study is to
describe the burden of disease that pemphigus causes to patients. A specific project was
started in February 2004: in addition to semistructured interviews and the administration of
the IPAT Anxiety Scale and the IPAT Depression Scale, the Medical Outcomes Study Short
Form 36 questionnaire (SF-36) was self-completed by the patients. Lower scores indicate
poorer QoL. 38 patients (19 men and 19 women) with pemphigus vulgaris completed the SF-
36. The physical scale scores were similar to the normative scores reported for ‘‘Major
medical conditions’’ in the SF-36 manual, while on the psychosocial scales QoL was
substantially more impaired in pemphigus (e.g., the ‘‘social functioning’’, ‘‘emotions’’, and
‘‘mental health’’ scores for the major medical conditions were always approx. 80, while in
pemphigus they were 58, 50, and 55, respectively). On the physical scales men and women
had similar scores, while on the psychosocial scales women had poorer QoL than men.Our
study shows that pemphigus has a great impact on the physical, social, and emotional
aspects of QoL. The systematic use of a generic QoL questionnaire is feasible in a routine
clinical setting, and it yields data useful both to dermatologists and psychologists.
P005
Rituximab in the Treatment of Severe Pemphigus Vulgaris: A Report of Five Cases
G. Cianchini G, M. Ruffelli, R. Corona, F. Canzona, C. Girardelli, R. Cecchi, B. Didona,
and P. Puddu
Dept. Of Immunodermatology. I Division of Dermatology. ^Hospital of Pistoia. Allergology
and Immunology Laboratory Istituto Dermopatico Dell’immacolata, Rome-Italy
Pemphigus vulgaris is an autoimmune bullous disease associated with the presence of
autoantibodies against desmogleins. Recently, there have been some reports on use of
rituximab, a monoclonal antibody directed against CD-20, a molecule expressed on mature B
lymphocytes, in severe pemphigus vulgaris patients. We report five cases, three male and
two female, aged from 27 to 63, affected with severe pemphigus vulgaris resistent to
conventional therapy, that received rituximab, 375 mg per m2 for four weekly consecutive
times. All five cases had a prompt response after treatment, with no serious side effects and
after a follow-up of six months are in good conditions, with a no-active or low-active disease,
and are treated with low dosage of corticosteroids. The ELISA titles of autoantibodies against
desmogleins slowly declined during this period. Rituximab is an effective and well tolerated
treatment for severe pemphigus vulgaris. Its use is relatively simple but very expensive and is
to be reserved to those cases which are resistent to all other therapies. We underline the low
incidence of side effects, expecially infections, in our patients.
P006
A Prospective Analysis on Anti-Desmoglein Antibody Proﬁles in Patients with
Rheumatoid Arthritis Treated with Thiol Compounds
T. Hamada1, T. Yamamoto1, Y. Hisamatsu1, M. Takata1, W. Fujimoto2, K. Taneichi3, and K.
Iwatsuki1
1Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry
and Pharmaceutical Sciences, 2Department of Dermatology, Kawasaki Medical School,
3Department of Internal Medicine, Kitami Red Cross Hospital
Purpose: We studied alteration of anti-desmoglein (Dsg) antibody profiles in a prospective
manner in patients with RA during the treatments with thiol compounds such as D-
penicillamine and bucillamine.
Methods: Anti-Dsg antibody profiles determined by ELISA were compared in the same group
of RA patients in a 2-year interval. The first screening test was performed in 204 patients
including 169 treated with thiol compounds, and the second test was performed in 139
including 124 treated with them. Positive sera were further analyzed by indirect immuno-
fluorescence (IIF) and immunoblotting (IB).
Results: In the first test period, eleven of 204 sera were Dsg- positive, and three were IB-
positive. In the second period, six of 139 were Dsg- positive, and five were IB- positive. All
positive sera except one were obtained from RA patients treated with thiols. During the
observation period, no patients progressed to ‘true’ pemphigus.
Conclusion: RA patients’ sera contain non-pathogenic antibodies reactive with Dsg by
ELISA. The antigenic determinants reactive with the sera might be different from the native
Dsgs.
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Chrysotherapy of 13 Patients with Pemphigus Vulgaris Refractory to Previous Therapies
P. Iranzo, M. Alsina, S. Segura, I. Martinez-de Pablo, J. Mascaro´, and C. Herrero
Dep. Dermatology, Hospital Clı´nic, Barcelona. Spain
Objective: To review the outcome of intramuscular gold treatment over a five-year period in
13 patients with pemphigus vulgaris refractory to previous therapies.
Methods: All patients received corticosteroids in combination with aurothiomalate. To assess
disease activity and gold toxicity, clinical and laboratory monitoring were weekly performed.
Corticosteroids dose was gradually tapered following clinical improvement, and the
frequency of injection of aurothiomalate was decreased. Once the patient was in clinical
remission, direct immunofluorescence (DIF) on normal skin was realized before therapeutic
discontinuation.
Results: Six patients are in total remission, without treatment. One is in remission, still on
therapy. In four patients it was possible to reduce prednisone doses but pemphigus flared
when prednisone dose was completely discontinued (one patient) and reduced in the other
three patients. Two patients presented side effects and therapy was discontinued. Patients
with negative DIF remain in complete remission for a mean period of 27,8 months after
therapy discontinuation.
Conclusions: Chrysotherapy allowed therapy discontinuation in 50% of patients with
refractory pemphigus, and a reduction of prednisone dosage in the remaining. Few side
effects were observed, always reversible with drug discontinuation. Gold therapy has shown
efficacy as secondary line treatment in refractory pemphigus vulgaris.
A carefully monitoring is mandatory to detect early toxicity.
P008
The Study of a Patient who Shifted from Paraneoplastic Pemphigus to Pemphigus
Vulgaris
N. Ishii and T. Hashimoto
Department of Dermatology, Kurume University School of Medicine, 67 Asahimachi,
Kurume, Fukuoka 830-0011
There are a number of reports of cases, which showed the clinical transition between
pemphigus vulgaris and pemphigus foliaceus. The change of the clinical phenotype
correlated with the changes of the target antigens. We report a 54-year-old Japanese female
case of paraneoplastic pemphigus (PNP), who had non-Hodgkin B-cell lymphoma with
diffuse medium size. The immunofluorescence of rat bladder sections showed the reactivity
with transitional epithelia, immunoblotting of human epidermal extracts showed the reactivity
with envoplakin and periplakin, and enzyme-linked immunosorbent assay (ELISA) detected
anti-Dsg3 antibodies. The patient became remission after the combination therapy of oral
steroid and plasmapheresis. All the immunofluorescence, immunoblotting and ELISA tests
became negative. However, subsequently, the patient showed recurrence of oral mucosal
membrane lesions. At this stage, immunofluorescence of rat bladder sections and
immunoblotting were negative, but ELISA showed the raise of anti-Dsg3 antibodies. We
considered that this case shifted from PNP to pemphigus vulgaris. This study should provide
us with important insights for the relationship between PNP and pemphigus vulgaris.
P009
Anti-Dsg1 and Anti-Dsg3 Antibodies are Prevalent in Tunisian Patients with Echinococ-
cosis and Leishmaniasis
M. Kallel Sellami, W. Tombari, M. Zitouni, L. Laadhar, B. Fezaa, M. Mokni, L. Mokhta, A. Ben
Osman, M. Kamoun, P. Joly, F. Tron, D. Gilbert, and S. Makni
The ‘‘Franco-Tunisian group of survey and research on the pemphigus’’
1) Recent data demonstrated that in endemic area of Brazilian pemphigus, anti-Desmoglein
antibodies are prevalent in patients with parasitic diseases thus suggesting a possible
involvement of these micro organisms in the etiopathogenesis of pemphigus.
The aim of this study is to search anti-desmoglein antibodies in two endemic parasitosis in
Tunisia: echinococcosis and leihmaniasis.
2) Material and Methods:
Serum samples were obtained from 35 patients with echinococcosis, 23 patients with
visceral leishmaniasis and 8 patients with cutaneous leishmaniasis.
Anti-dsg1 and 3 antibodies were detected by a commercial ELISA (MBL). For IgG subclass
studies, we used anti-human IgG1, IgG2, IgG3 and IgG4 murine MoAb.
3) Results:
In patients with echinococcosis, anti-Dsg1 and Anti-Dsg3 antibodies were detected in 14
(40%) and 3 (8%, 5%) cases respectively.
In patients with visceral leishmaniosis, anti-Dsg1 and anti-Dsg3 antibodies were detected
in 5 (21%) and 3 (17%) cases respectively.
Sub class studies showed that anti-Dsg antibodies were IgG1 and or IgG2.
4) Conclusion: our results confirm that anti-desmoglein antibodies are prevalent in patients
with parasitic diseases suggesting a possible link of these environmental factors to
endemicTunisian pemphigus.
P010
Prevalence of Anti-Desmoglein-1 and -3 Antibodies in Tunisian Endemic Pemphigus
M. Kallel Sellami, O. Abida, M. Zitouni, M. Ben Ayed, M. Mokni, H. Turki, B. Fezza, I.
Mokhtar, A. Ben Osman, M. Kamoun, P. Joly, F. Tron, D. Gilbert, H. Masmoudi, and S. Makni
The ‘‘Franco-Tunisian group of survey and research on the pemphigus’’
1) Two case/control studies were conducted in two different Tunisian regions: the north and
the south to determine the frequency of anti-desmoglein 1 (anti-Dsg1) and anti-desmoglein 3
(anti-Dsg3) in Tunisian endemic pemphigus (P) compared to healthy subjects.
2) Material and Methods:
In the north region, Serum samples were obtained from 59 P foliaceus patients, 65
P vulgaris patients and 154 controls.
In the south region, Serum samples were obtained from 40 P foliaceus patients, 12
P vulgaris patients and 120 controls.
3) Results:
P foliaceus P vulgaris Controls
Anti-Dsg1 Anti-Dsg3 Anti-Dsg1 Anti-Dsg3 Anti-Dsg1 Anti-Dsg3
North 93% 12% 70% 86% 6.5% 3%
South 75% 7.5% 75% 91% 8.3% 9.1%
4) Conclusion: we found comparable prevalences of anti-Dsg1 and anti-Dsg3 antibodies in
both northern and southern pemphigus patients. However the prevalence of anti-Dsg1 and
anti-Dsg3 antibodies was higher in southern healthy subjects living in rural areas (15,8 versus
7,9% in the north, p¼o,o3). The high prevalence of anti-desmoglein antibodies in healthy
Tunisian subjects living in endemic area is along with a major role of environmental factors in
the occurrence of Tunisian endemic P.
P011
Inhibition of Epidermal Cholinergic Receptors Promotes Acantholysis and Apoptosis in
Organotypic Cocultures
H. Kurzen, D. Booken1, C. Henrich1, and N. Maas-Szabowski2
1University Medical Center Mannheim, University of Heidelberg, Department of Dermatol-
ogy, 68135 Mannheim, Germany. 2German Cancer Research Center, 69120 Heidelberg,
Germany
The aim of the present study was to analyse the influence of cholinergic (nicotine, carbachole,
muscarine) and anticholinergic drugs (mecamylamine, atropine, strychnine) on epidermal
physiology using organotypic cocultures (OTC) as an in vitro skin equivalent system.
Immunofluorescence analysis was performed using the TUNEL reaction, a panel of antibodies
against apoptosis markers and adhesion molecules. Blocking of all acetylcholine receptors
(ACh-R) for 5-10 days completely inhibited formation of an intact epithelium. Blockage of
nicotinic (n)ACh-R with mecamylamine led to a less pronounced delay in epidermal
differentiation than blockage of muscarinic (m)ACh-R with atropine, evidenced by reduced
epithelial thickness. In OTCs treated with atropine, mecamylamine or strychnine (which blocks
a9 ACh-R), we could demonstrate prominent acantholysis in the basal and lower suprabasal
layers, accompanied by a global down-regulation of desmosomal proteins (desmoglein 3,
plakoglobin) as well as adherens junction proteins (E-cadherin, b-catenin). In addition,
apoptosis was prominent as evidenced by TUNEL assay and activated caspase 3. In contrast,
stimulation of nACh-R and mACh-R with cholinergic drugs, resulted in a significantly thickened
epithelium with slightly increased expression of adhesion molecules. We conclude that
inhibition of epidermal ACh-R severely disrupts epidermal homeostasis. In particular, cell
adhesion and apoptosis are influenced by both nicotinic and muscarinic ACh-R.
P012
Clinical Value of Desmoglein-1 and -3 Antibody Reactivity Measurments in Patients with
Pemphigus
K. Leiferman, M. Tuttle, and J. Zone
Dept of Dermatology, University of Utah, Salt Lake City, UT 84132-2409 USA
Purpose: To compare cell surface (CS), desmoglein (dsg)1 and 3 antibody (ab) reactivity in
patients with known pemphigus over time.
Methods: 245 serum specimens from 25 pemphigus patients with three or more sera
collected between 1994 and 2005 were assayed for IgG CS ab by indirect immunofluores-
cence (IIF) on intact human skin and monkey esophagus and IgG dsg1 and dsg3 ab by ELISA.
Pearson’s correlation analyses were used to compare IIF CS titers to ELISA dsg1 and dsg3
levels, and the average dsg1 and dsg3 levels.
Results: In individual patients, dsg1 or dsg3 ab levels correlated with IIF CS ab titers, average
r¼ 0.50. Dsg1 ab levels correlated with IIF CS ab titers on intact skin, r¼ 0.48, po0.01, and
Dsg3 levels correlated with IIF CS titers on monkey esophagus, r¼ 0.52, po0.01. Overall, the
average of dsg1 and dsg3 levels correlated with IIF CS titers, r¼ 0.49, po0.01. In certain
patients, reactivity patterns changed over time; for example, dsg3 ab decreased whereas
dsg1 ab increased. Other patients showed changes in levels with increases in the
nondominant antibody level such that nearly equal levels of dsg1 and dsg3 ab were present
over time. With clinical improvement, all elevated ab levels decreased, and dsg1 and 3 ab
levels appeared to be more sensitive indicators of disease activity than CS titers.
Conclusion: Dsg ab levels not only help diagnostically for subtyping pemphigus but are
better disease activity correlates than CS ab titers. Thus, these results show that
measurement of dsg ab is clinically useful in patients with pemphigus and that dsg ab
patterns change with time.
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Tumor Necrosis Factor (-238 G/A) Gene Promotor Polymorphism in Tunisian Pemphigus
Foliaceus Patients
H. Masmoudi1, H. Affes1, M. Ben Ayed1, O. Abida1, A. Masmoudi2, and H. Turki2
1Laboratory of Immunology, Habib Bourguiba University Hospital of Sfax, Tunisia,
2Dermatology Department, Hedi Chaker University Hospital of Sfax, Tunisia
Pemphigus foliaceus (PF) is an auto-immune blistering skin disease characterized by the
production of auto-antibodies directed against a desmosomal protein : the desmoglein1. It is
a rare disease throughout the world but it has an endemic form in Brazil, Colombia and in
Tunisia. It is a multi-factorial disease where the genetic and environmental factors interact
and participate in the appearance of the disease.
To investigate these genetic factors, we chose in this work to study the tumor nescosis
factor alpha (TNFa) promoter gene polymorphism at position 238 (G/A) which has been
incriminated as genetic factor in others auto-immune diseases.
We achieved a case-control study on 40 patients from South of Tunisia affected by PF
matched in age, sex and geographical origin with 120 healthy controls (3 controls/patient).
The polymorphism of TNFa promoter gene has been studied by PCR-RFLP using the MSP1
enzymatic digestion. This technique permits to differentiate the homozygous, heterozygous
and non mutated subjects.
The frequency of the mutation was 10% (8/80) in patients against 8% (19/240) among the
controls. This difference is not statistically significant (w2¼0, 33. r¼ 0, 56). Whereas the
frequency of the homozygous mutation was statistically different in patients (5%) compared
to controls (0%) (w2¼ 6,075. r¼0,013).
Thereby, the homozygous mutation in TNFa promoter gene (238A) seems to be
associated to the Tunisian PF. This result have to be confirmed on a larger population.
P014
Tunisian Pemphigus Foliaceus: Familial Cases
H. Masmoudi2, H. Turki1, O. Abida2, M. Ben Ayed2, A. Masmoudi1, D. Gilbert3, F. Tron3, and
P. Joly4
1Dermatology Department, Hedi Chaker University Hospital of Sfax, Tunisia, 2Laboratory of
Immunology, Habib Bourguiba University Hospital of Sfax, Tunisia, 3Laboratory of
Immunology, Medicine School of Rouen, France, 4Laboratory of Immunology, Charles
Nicolle University Hospital of Rouen, France
The Tunisian pemphigus foliaceus (PF) presents particular epidemiological features. In
previous multicentric studies, no single family case has been detected. The intervening of a
PF at 2 sisters pushed us to search for other family cases.
For that, we have retaken all pemphigus files. At first, we have classified patients by regions
and/or by family name. First of all, every patient has been asked about the existence of other
cases in his family having a dermatological problem. Thereafter this cross-examination was
oriented toward a blistering skin disease. To confirm this family attack, we moved to those
areas for further exploration.
This procedure allowed us to discover, in addition to the first family with 2 sisters affected
with PF, 4 other multiplex PF families, all living in farming regions of the Tunisian south
(Mareth, Moknassy and Jebeniana). The patients affected by PF were two cousins in each
family; a man and a woman in a family and two women in the other ones. Among these last
three families, one included another cousin affected by bullouse pemphigoide, yet in another
of these families one of the affected cousins had a one-year son who is also affected by IgA
pemphgoide. In addition to these 5 families of PF, we have discovered a sixth family,
composed of three cousins affected by different skin blister disease: the first had a PF
occurring at the age of 27 years old in 2000, the second had pemphigus vulgaris occurring at
the age of 52 years old in 2003 and the third one had a gestationis pemphigoide at the age of
35 old in 1997. It’s important to note that all the mentioned patients are followed in our
dermatology department but this familial history has not been identified before this ‘‘police’’
cross-examination.
Thus, there are 138 deducted members. Only 68 of them have benefited from the research
of anti-desmogleine (Dsg) 1 and anti-Dsg3 antibodies. Five related have been proved positive
in anti-Dsg1 (7.35%), 3 among them were also positive in anti-Dsg3. The rest of the
serological survey as well as the HLA II typing are in progress.
This work allows us to note that there are some similarities marked between Tunisian and
Brazilian endemic pemphigus as testifies the existence of these Tunisian’s multiplex families.
These results could translate the existence of two shapes of PF in Tunisia, a sporadic and a
familial shape, of which the immunogenetical determinism and the epidemiological
characteristics remain to be precised.
P015
HLA DR3 is Associated with Tunisian Pemphigus Foliaceus
H. Masmoudi, O. Abida, M. Zitouni, M. Ben Ayed, N. Mahfoudh, M. Kallel, M. Mokni, A.
Kammoun, B. Fazaa, M. Kammoun, H. Makni, D. Gilbert, F. Tron, P. Joly, H. Turki, and S.
Makni
The ‘‘Franco-Tunisian group of survey and research on the pemphigus’’
The pemphigus foliaceus (PF) is an auto-immune blistering disease in the determinism of
which intervene environmental and genetic factors. The HLA system is the most studied
genetic component. However no publication exists in relation with the Tunisian endemic
shape.
The purpose of our work was to establish the HLA-II antigens of susceptibility and
protection in Tunisian PF. For that, we collected 40 PF patients from Tunisian south; matching
in age, sex and geographical origin to 120 healthy controls; and 57 PF patients from the north
of the country. The HLA-II typing as well as the under DR4 typing (realized solely for the
cohort of the south) were done by a polymerase chain reaction sequence specific primer
(PCR-SSP).The significance of differences in HLA antigen frequencies was calculated by chi-
square. The strength of HLA associations with disease was estimated by odds ratio. The p
values were corrected by multiplying by the number of alleles analysed.
After Bonferroni’s correction, the statistical study of the HLA class II alleles showed
association of the Tunisian PF with HLA DRB103, 0402, 0404, 0405, and DQB10302, for
the cohort of the south. In contrast, the expression of the DRB115, DQB10301 and 06
confered a protection against the Tunisian PF. Indeed, haplotypes DRB103/DQB102 and
DRB10402/DQB10302 constitute susceptibility haplotype to PF; while DRB115/DQB106
and DRB111/DQB10301 haplotype were found to be protective.
On the other hand, in Tunisian north, only DRB101 and DRB104 were found as
susceptibility alleles, after Bonferroni’s correction. DRB103 was rejected after this
correction. In addition, DRB101/DQB105 and DRB104/DQB105 were found as
susceptibility haplotypes to PF.
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Correlation Between Antidesmoglein Antibodies Titers, Determined by ELISA, and
Clinical Follow-Up in Pemphigus Vulgaris
K. Moreno Va´zquez, I. Becker Fauser, A. Ruiz Remigio, and G. Leo´n Dorantes
Dermatology Department, Hospital General de Me´xico, Me´xico City, Me´xico.
Background: Pemphigus vulgaris (PV) is an autoimmune blistering disease. Patients with PV
develop IgG autoantibodies against desmogleins. Indirect immunofluorescence has been
widely used for decades to determine these antibodies, more recently another method was
developed, by using ELISA for the detection of antidesmoglein antibodies. This method and
its clinical correlation has not been evaluated.
Objective: To evaluate the correlation between antidesmoglein antibodies titers by using the
ELISA method and the disease activity of pemphigus, and its phenotypes, over time.
Patients/Methods: Sera were obtained from 34 patients with diagnosis of PV over the course
of the disease, as well as a clinical evaluation. 168 samples were analysed by the ELISA
method to determine the presence of antidesmoglein 1 and 3.
Results: Of the 168 sera, 55 (32%) were of the activity phase 25 (15%) of the control phase,
48 (29%) in the consolidation phase and 40 (24%) in remission phase. Of the 34 patients, 14
(41%) presented mucosal dominant phenotype, 20 (59%) patients presented mucocutaneous
phenotype.
Conclusions: The results of sera of patients with mucosal dominant pemphigus did not
correlate with the clinical phase. Thus, for patients with mucocutaneous pemphigus there
was a strong relation between the autoantibodies titers and the clinical phases. The ELISA
method for the detection of antidesmoglein antibodies is useful for diagnosis, phenotype
classification, as well as for follow up, and possibly for management.
P017
Correlation Between Anti-Dsg By ELISA and Antiepithelium Antibodies by Indirect
Immunoﬂuorescence in the Follow-Up of Pemphigus Vulgaris
K. Moreno Va´zquez, E. Avalos Dı´az, I. Becker Fauser, A. Ruiz Remigio, and G. Leo´n
Dorantes
Dermatology Department , Hospital General de Me´xico, Me´xico City, Me´xico.
Background: Pemphigus vulgaris (PV) is an autoimmune blistering disease. Its autoimmune
features are IgG against desmogleins. Indirect immunofluorescence has been used for
decades to determine these antibodies, more recently another method was developed, by
ELISA for the detection of anti-Dsg. The specific value of this method for follow-up of PV has
not been evaluated.
Objective: To evaluate the relation between anti-Dsg determined through ELISA method and
antiepithelium antibodies determined through indirect immunofluorescence during clinical
follow-up.
Patients/Methods: Sera were obtained from 27 patients (19 females and 8 males) with
diagnosis of PV over the course of the disease, as well as a clinical evaluation. 125 samples
were analysed by the ELISA method to determine the presence of antidesmoglein 1 and 3 as
well as indirect immunofluorescence.
Results: Of the 125 sera, 33 (26%) were of the activity phase (incuding exacerbations and
relapses), 23 (19%) of the control phase, 40 (32%) in the consolidation phase and 29 (23%) in
remission phase. Of the 27 patients, 14 (51%) presented mucosal dominant phenotype, 13
(49%) patients presented mucocutaneous phenotype.
Conclusions: The anti-Dsg antibodies titers determined by ELISA do correlate with the
clinical phases of PV, although in many cases, there is a need to increase the dilution to better
assess the changes. The immunofluorescence method did not relate to the clinical phases.
P018
Kinetic Analysis of Antibody-Antigen Interaction in Pemphigus by Surface Plasmon
Resonance
K. Tsunoda and M. Amagai
Department of Dermatology, Keio University School of Medicine, Tokyo, Japan
Pemphigus vulgaris (PV) is an autoimmune blistering disease caused by IgG autoantibodies
against desmoglein (Dsg) 3. Previously, we have isolated AK series anti-mouse Dsg3 IgG
monoclonal antibodies (mAbs) from PV model mice with active PV phenotype. Each AK mAb
displayed different pathogenic activities in their ability to induce blisters in neonatal mice and
adult mice. The Epitope mapping of these mAbs indicated that most pathogenic AK23 mAb
recognized N-terminal adhesive interface of Dsg3 while other AK mAbs which failed to show
apparent pathogenic activity recognized the middle to C-terminal extracellular region of
Dsg3. Therefore, the epitope is an important factor to define the pathogenic activity of anti-
Dsg3 antibody. The purpose of this study is to determine the binding kinetics of AK mAb to
Dsg3 and correlate them with the pathogenic activity. We employed BIAcore surface plasmon
resonance to measure binding kinetics. Biacore can measure the rate how fast the molecule
can bind (k-on, s1) and how fast the molecule dissosiate (k-off, Ms1) respectively. These
two parameters are utilized to calculate the dissociation constant rate KD, (KD¼ k-off/k-on,
M). Hence smaller KD indicates stronger affinity. The anti-mouse IgG1 antibodies were
immobilized on sensorchip as ligands and then each AK mAbs was applied as a capturing
molecule. Mouse Dsg3 was applied as an analyte and binding curves of Dsg3 on AK mAb (k-
on) and those of dissociation of Dsg3 from AK mAb (k-off) were recorded at real time on
sensorgram. The binding kinetics of AK mAbs were widely ranged from 3.7nM to 23.2uM. The
binding affinity of AK mAbs to Dsg3 protein was heterogeneous. These findings suggest that
the binding kinetics of anti-Dsg3 IgG may be another important factor to define the
pathogenic strength.
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Evaluation of Different Serological Tests for the Diagnosis of Pemphigus
C. Vaschieri, A. Marconi, C. Pincelli, and A. Giannetti
Institute of Dermatology, University of Modena and Reggio Emilia, Modena, Italy
Pemphigus is a severe autoimmune blistering disease which requires an accurate and rapid
diagnosis. In the present study, we wanted to evaluate different serological methods for the
diagnosis of pemphigus. We collected serum from 13 patients with pemphigus vulgaris (PV)
and 8 patients with pemphigus foliaceous (PF). Diagnosis was based on the clinical features
and on the positive direct immunefluorescence (DIF). In order to compare the various
methods, indirect immunefluorescence (IIF) using normal human skin as substrate, western
blotting (WB), using normal human keratinocytes as substrate and ELISA were used. IIF
confirmed the results of DIF in 63% of PF and in 61% of PV patients, respectively. On the
other hand, ELISA assay correlated with DIF in 100% of cases. In particular, 38% of sera
reacted against desmoglein 1 (Dsg1, 160 kDa), 24% against Dsg3 (130 kDa) and 38% against
both Dsgs (mucocutaneous pemphigus). WB confirmed DIF results in 95% of cases. In
addition, 100% Dsg3 ELISA positive sera have shown a 130 kDa band, while 160 kDa band
was detected only in 80% Dsg1 positive sera. In the mucocutaneous form of PV, WB has
shown 130 kDa band in all sera, whereas 160 kDa band was detected in only 25% of cases.
This study indicates that ELISA and WB are more sensitive than IIF. Furthermore, ELISA was
shown to be more sensitive and more specific than WB, because not only it confirms 100% of
pemphigus cases, but also because it detects both PV and PF antigens. As ELISA is a rapid
and non invasive test, it could replace DIF as a first diagnostic tool for pemphigus.
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